Chardan Capital Markets lowered its price target on Regenxbio Inc. (NASDAQ: RGNX) to $127.50 (from $130.00) while maintaining a Buy rating following positive interim data from its phase I study of RGX-314 in wet AMD (NCT03066258) and to us negative interim data in its phase I/II study of RGX-501 in HoFH (NCT02651675).

Analyst Gbola Amusa believes the bar is lower in wet AMD than many think. Amusa said what the market is missing: "Real world outcomes data show patients on anti-VEGF therapies (Avastin, Eylea, Lucentis) are losing vision due to lack of compliance. We note recent views in the market saying hurdles are high for RGX-314 due to the success of Lucentis and Eylea (and Avastin) in boosting vision in clinical trials. We note though that in the real world, due to the requirement of injecting Lucentis and Eylea into the eye on a monthly or bi-monthly basis, most patients are sub-optimally treated/compliant and thus often lose vision after starting anti-VEGF therapy."